PL2803662T3 - Antagonista receptora p2x4 - Google Patents

Antagonista receptora p2x4

Info

Publication number
PL2803662T3
PL2803662T3 PL13736295T PL13736295T PL2803662T3 PL 2803662 T3 PL2803662 T3 PL 2803662T3 PL 13736295 T PL13736295 T PL 13736295T PL 13736295 T PL13736295 T PL 13736295T PL 2803662 T3 PL2803662 T3 PL 2803662T3
Authority
PL
Poland
Prior art keywords
receptor antagonist
antagonist
receptor
Prior art date
Application number
PL13736295T
Other languages
English (en)
Inventor
Masatoshi Ushioda
Kunio Kobayashi
Daisuke Saito
Shogo Sakuma
Toshiyasu Imai
Kazuhide Inoue
Original Assignee
Nippon Chemiphar Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemiphar Co., Ltd. filed Critical Nippon Chemiphar Co., Ltd.
Publication of PL2803662T3 publication Critical patent/PL2803662T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/121,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/181,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL13736295T 2012-01-13 2013-01-10 Antagonista receptora p2x4 PL2803662T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012005343 2012-01-13

Publications (1)

Publication Number Publication Date
PL2803662T3 true PL2803662T3 (pl) 2017-09-29

Family

ID=48781550

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13736295T PL2803662T3 (pl) 2012-01-13 2013-01-10 Antagonista receptora p2x4

Country Status (16)

Country Link
US (5) US9382236B2 (pl)
EP (1) EP2803662B1 (pl)
JP (1) JP6207399B2 (pl)
KR (2) KR102140746B1 (pl)
CN (4) CN108863959B (pl)
AU (1) AU2013208536B2 (pl)
CA (1) CA2861024C (pl)
DK (1) DK2803662T3 (pl)
ES (1) ES2626036T3 (pl)
HK (1) HK1203191A1 (pl)
IL (1) IL233592B (pl)
NZ (1) NZ627878A (pl)
PL (1) PL2803662T3 (pl)
PT (1) PT2803662T (pl)
SG (2) SG10201605325TA (pl)
WO (1) WO2013105608A1 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2803662B1 (en) 2012-01-13 2017-03-01 Nippon Chemiphar Co., Ltd. P2x4 receptor antagonist
ES2753422T3 (es) * 2013-07-12 2020-04-08 Nippon Chemiphar Co Antagonista de receptor P2X4
AU2014288116B2 (en) 2013-07-12 2018-05-17 Kyushu University P2X4 receptor antagonist
WO2015088565A1 (en) * 2013-12-13 2015-06-18 Sunovion Pharmaceuticals Inc. P2x4 receptor modulating compounds and methods of use thereof
EP3274336A4 (en) 2015-03-24 2018-11-14 Piramal Enterprises Limited An improved process for the preparation of clobazam and its intermediate
WO2016183266A1 (en) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Ehpatitis b antiviral agents
ES2938341T3 (es) 2016-03-07 2023-04-10 Enanta Pharm Inc Agentes antivirales contra la hepatitis B
CA3022358A1 (en) 2016-04-28 2017-11-02 Nippon Chemiphar Co., Ltd. Medicament for treatment of multiple sclerosis
MA45020B1 (fr) 2016-05-03 2020-11-30 Bayer Pharma AG Dérivés sulfonamides aromatiques
WO2018104305A1 (en) 2016-12-09 2018-06-14 Bayer Pharma Aktiengesellschaft Field of application of the invention
WO2018104307A1 (en) 2016-12-09 2018-06-14 Bayer Pharma Aktiengesellschaft Aromatic sulfonamide derivatives and their use as anatagon i sts or negative allosteric modulators of p2x4
WO2018210729A1 (en) 2017-05-18 2018-11-22 Bayer Pharma Aktiengesellschaft Aromatic sulfonamide derivatives as antagonists or negative allosteric modulators of p2x4 receptor
WO2019046271A1 (en) 2017-08-28 2019-03-07 Enanta Pharmaceuticals, Inc. ANTIVIRAL AGENTS AGAINST HEPATITIS B
WO2019143902A2 (en) 2018-01-22 2019-07-25 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2019177117A1 (ja) 2018-03-14 2019-09-19 日本ケミファ株式会社 咳嗽の治療のための医薬
JPWO2020050253A1 (ja) * 2018-09-03 2021-08-30 日本ケミファ株式会社 糖尿病性末梢神経障害のための医薬
MX2021003253A (es) 2018-09-21 2021-08-11 Enanta Pharm Inc Heterociclos funcionalizados como agentes antivirales.
AU2019385477A1 (en) 2018-11-21 2021-06-10 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2020247561A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
EP4085056A1 (en) 2020-01-03 2022-11-09 Berg LLC Polycyclic amides as ube2k modulators for treating cancer
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
CA3174216A1 (en) * 2020-03-30 2021-10-07 Luca ANTONIOLI Medicament for preventing or treating irritable bowel syndrome or inflammatory bowel disease
AU2021301158A1 (en) 2020-06-30 2022-12-15 Bayer Aktiengesellschaft Use of N-phenylacetamides having P2X4 receptor antagonistic activity for treating certain ocular disorders
WO2022002859A1 (en) 2020-06-30 2022-01-06 Bayer Aktiengesellschaft Substituted n-phenylacetamides having p2x4 receptor antagonistic activity
CN116437928A (zh) 2020-08-03 2023-07-14 日本化学药品株式会社 用于预防、抑制或治疗伴随着过敏反应的症状的医药组合物
WO2022049253A1 (en) 2020-09-07 2022-03-10 Bayer Aktiengesellschaft Substituted n-heteroaryl-n-pyridinylacetamides as p2x4 modulators
CA3220039A1 (en) 2021-06-14 2022-12-22 Jr. David St. Jean Urea derivatives which can be used to treat cancer
IT202100025124A1 (it) 2021-09-30 2023-03-30 Univ Degli Studi Di Firenze Medicamento per uso nel prevenire o trattare il dolore nocicettivo e/o viscerale
CA3233194A1 (en) 2021-09-30 2023-04-06 Toshiyasu Imai Agent for preventing or treating respiratory disease
WO2023157895A1 (ja) * 2022-02-17 2023-08-24 国立大学法人 鳥取大学 子宮内膜症又は子宮腺筋症の予防又は治療剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5534960Y2 (pl) 1977-01-31 1980-08-18
JPS53111093A (en) * 1977-03-07 1978-09-28 Takeda Chem Ind Ltd Imidazo(1,5-d)(1,4)benzodiazepin derivative and its preparation
JPH02304437A (ja) 1989-05-19 1990-12-18 Konica Corp 新規な写真用カプラー
HUT76135A (en) * 1994-04-14 1997-06-30 Glaxo Wellcome Inc Cholecystokinin and gastrin modulating 5-heterocyclic-1,5-benzodiazepines
PE27497A1 (es) * 1994-04-15 1997-08-07 Glaxo Inc Derivados de 1,5 benzodiazepina
SE0104250D0 (sv) 2001-12-14 2001-12-14 Astrazeneca Ab Heterocyclic compounds
US20060128695A1 (en) * 2002-10-30 2006-06-15 Neuro3D Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses
DE10312969A1 (de) * 2003-03-24 2004-10-07 Bayer Healthcare Ag Benzofuro-1,4-diazepin-2-on-Derivate
US20050074819A1 (en) 2003-10-01 2005-04-07 Japan Health Sciences Foundation Screening method of drug for treatment of neuropathic pain
KR100512749B1 (ko) 2004-01-14 2005-09-07 삼성전자주식회사 모니터장치
US20100298285A1 (en) 2006-03-16 2010-11-25 Kelly Michael G Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof
JPWO2008023847A1 (ja) 2006-08-25 2010-01-14 日本ケミファ株式会社 P2x4受容体拮抗剤
RS53042B (en) 2007-02-16 2014-04-30 Merrimack Pharmaceuticals Inc. ANTIBODIES AGAINST ERBB3 AND THEIR USES
JP2012087053A (ja) * 2009-02-03 2012-05-10 Nippon Chemiphar Co Ltd ジアゼピンジオン誘導体
CN102395577B (zh) 2009-02-16 2014-04-23 日本化学医药株式会社 二氮杂*二酮衍生物
KR101890441B1 (ko) * 2010-07-13 2018-08-21 닛뽕 케미파 가부시키가이샤 P2x4 수용체 길항제
JP2013209292A (ja) * 2010-07-23 2013-10-10 Nippon Chemiphar Co Ltd P2x4受容体拮抗剤
JP6325252B2 (ja) * 2011-05-25 2018-05-16 国立大学法人九州大学 ギラン・バレー症候群に伴う神経因性疼痛の予防又は治療剤
EP2803662B1 (en) 2012-01-13 2017-03-01 Nippon Chemiphar Co., Ltd. P2x4 receptor antagonist

Also Published As

Publication number Publication date
HK1203191A1 (en) 2015-10-23
KR102092147B1 (ko) 2020-03-23
US20140357858A1 (en) 2014-12-04
US10633349B2 (en) 2020-04-28
US9969700B2 (en) 2018-05-15
US20220380322A1 (en) 2022-12-01
US11434207B2 (en) 2022-09-06
EP2803662A4 (en) 2015-06-03
IL233592B (en) 2018-08-30
KR102140746B1 (ko) 2020-08-04
US20160280667A1 (en) 2016-09-29
EP2803662B1 (en) 2017-03-01
CN104066724B (zh) 2020-04-17
CN111333588A (zh) 2020-06-26
JP6207399B2 (ja) 2017-10-04
PT2803662T (pt) 2017-04-05
NZ627878A (en) 2016-03-31
CN108863959A (zh) 2018-11-23
CN104066724A (zh) 2014-09-24
US9382236B2 (en) 2016-07-05
AU2013208536B2 (en) 2017-07-20
WO2013105608A1 (ja) 2013-07-18
AU2013208536A1 (en) 2014-08-21
EP2803662A1 (en) 2014-11-19
CA2861024A1 (en) 2013-07-18
CN110483423A (zh) 2019-11-22
SG10201605325TA (en) 2016-08-30
KR20200032762A (ko) 2020-03-26
DK2803662T3 (en) 2017-05-01
ES2626036T3 (es) 2017-07-21
US20180201587A1 (en) 2018-07-19
KR20140116926A (ko) 2014-10-06
IL233592A0 (en) 2014-08-31
CN108863959B (zh) 2021-11-30
CA2861024C (en) 2020-09-22
SG11201404030YA (en) 2014-10-30
US20200223806A1 (en) 2020-07-16
JPWO2013105608A1 (ja) 2015-05-11

Similar Documents

Publication Publication Date Title
HK1203191A1 (en) P2x4 receptor antagonist p2x4
HK1211039A1 (en) Engineering -cell receptors
HK1252279A1 (zh) 5- ht3受體拮抗劑
GB201213700D0 (en) Receptor antagnists II
EP2911675A4 (en) 2-PYRIDYLOXY-3-SUBSTITUTED 4-NITRIL-OREXINE RECEPTOR ANTAGONISTS
EP2934527A4 (en) ANTAGONIST 2-PYRYDYLOXY-4-ESTER COMPOUNDS OF OREXIN RECEPTORS
EP2934516A4 (en) ANTAGONISTS OF 3-ESTER-4-SUBSTITUTED OREXIN RECEPTORS
EP2925321A4 (en) 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
EP2934517A4 (en) 4-SUBSTITUTED 2-PYRYDYLOXY-3-NITRILE OREXIN RECEPTOR ANTAGONISTS
EP2908812A4 (en) 2-pyridyloxy, 3-ESTER-4-NITRILOREXIN receptor antagonists
EP3020707A4 (en) ANTAGONIST OF P2X4 RECEPTORS
EP3020717A4 (en) P2x4 receptor antagonist
EP2665707A4 (en) Mineralocorticoid receptor antagonists
EP2619204A4 (en) TRIAZOLOPYRAZINONES AS ANTAGONISTS OF P2X7 RECEPTORS
EP2765860A4 (en) Mineralocorticoid receptor antagonists
HK1192228A1 (zh) 受體拮抗劑
EP2617717A4 (en) ANTAGONIST OF P2X4 RECEIVER
HK1205104A1 (en) Novel neurokinin receptor antagonist compounds
EP2697203A4 (en) ANTAGONISTS OF MINERALOCORTICOID RECEPTORS
EP2874621A4 (en) Mineralocorticoid receptor antagonists
EP2765859A4 (en) Mineralocorticoid receptor antagonists
EP2765858A4 (en) ANTAGONISTS OF A MINERALOCORTICOID RECEPTOR
GB201223053D0 (en) Receptor
GB201213699D0 (en) Receptor antagonists II
GB201213698D0 (en) Receptor antagonists II